Table 2.
NC | mSTF | PE ± SD* | 95% CI | P-Value | |
---|---|---|---|---|---|
Infection | 2 (3.4%) | 4 (7.3%) | 0.07 ± 0.04 | 0.01–0.15 | 0.097 |
Fatigue | 22 (37.9%) | 25 (45.5%) | -0.01 ± 0.09 | − 0.20 – 0.17 | 0.882 |
Insomnia | 2 (3.4%) | 4 (7.3%) | 0.03 ± 0.04 | − 0.05 – 0.11 | 0.505 |
Headachesa | 2 (5.7%) | 0 | −0.03 ± 0.06 | − 0.14 – 0.09 | 0.649 |
Dizzinessa | 3 (8.6%) | 2 (7.1%) | −0.10 ± 0.07 | −0.25 – 0.05 | 0.187 |
Depression | 2 (3.4%) | 2 (3.6%) | − 0.02 ± 0.04 | − 0.10 – 0.06 | 0.560 |
Nausea | 22 (37.9%) | 16 (29.1%) | − 0.01 ± 0.10 | −0.21 – 0.18 | 0.895 |
Vomiting | 0 | 2 (3.6%) | 0.02 ± 0.03 | −0.03 – 0.08 | 0.413 |
Diarrhea | 2 (3.4%) | 2 (3.6%) | −0.01 ± 0.04 | −0.09 – 0.07 | 0.877 |
Obstipationb | 5 (8.8%) | 4 (7.3%) | −0.02 ± 0.06 | −0.13 – 0.09 | 0.688 |
Stomach painsa | 1 (2.9%) | 0 | −0.02 ± 0.04 | −0.10 – 0.07 | 0.695 |
Reduced appetitea | 7 (20.0%) | 2 (7.1%) | −0.16 ± 0.11 | −0.39 – 0.06 | 0.150 |
Hungerc | 2 (5.6%) | 0 | −0.03 ± 0.06 | −0.15 – 0.09 | 0.606 |
Stomatitis | 15 (25.9%) | 3 (5.5%) | −0.16 ± 0.06 | −0.28 – (− 0.03) | 0.013 |
Esophagitis | 2 (3.4%) | 2 (3.6%) | 0.01 ± 0.04 | − 0.08 – 0.09 | 0.892 |
Neuroses | 8 (13.8%) | 10 (18.2%) | 0.07 ± 0.07 | −0.06 – 0.20 | 0.280 |
Arthralgia | 1 (1.7%) | 2 (3.6%) | 0.02 ± 0.03 | −0.05 – 0.09 | 0.614 |
Pain | 11 (19%) | 3 (5.5%) | − 0.11 ± 0.06 | −0.23 – 0.01 | 0.075 |
Dyspnea | 0 | 2 (3.6%) | 0.03 ± 0.02 | − 0.01 – 0.07 | 0.098 |
Oedemas | 0 | 1 (1.8%) | 0.0 ± 0.02 | −0.04 – 0.04 | 0.840 |
Values are shown as mean ± SD. Due to missing data, we included data of 58 cycles of NC and 55 cycles of mSTF in this analysis.*PE ± SD represents the difference for CTCAE points between cycles of NC and those of mSTF. All side effects were scored according to CTCAE v.4.0. Each side effect was scored once per patient during each chemotherapy cycle. a n = 63; b n = 112; c n = 64